PCNA-I1 – 25 mg

Brand:
Cayman
CAS:
444930-42-1
Storage:
-20
UN-No:
Non-Hazardous - /

PCNA-I1 is an inhibitor of proliferating cell nuclear antigen (PCNA) that binds to PCNA trimers (Kd = 0.41 µM) and dose-dependently reduces the level of PCNA associated with chromatin in PC3 cells.{43201} It preferentially inhibits growth of a variety of human and mouse cancer cell lines (IC50s = 0.05-0.3 µM) over non-transformed cells (IC50s = 0.99-2 µM). PCNA-I1 leads to an accumulation of cells in the G1 phase during the first 24 hours of incubation and halts the cell cycle in the S and G2/M phases by 72 hours following treatment. It also reduces tumor growth in an LNCaP prostate cancer mouse xenograft model when administered at a dose of 10 mg/kg, five days per week, for two weeks.{43202}  

 

Available on backorder

SKU: 20454 - Category:

Description

An inhibitor of PCNA; binds to PCNA trimers (Kd = 0.41 µM) and reduces the level of chromatin-associated PCNA in PC3 cells; preferentially inhibits growth of a variety of human and mouse cancer cell lines (IC50s = 0.05-0.3 µM) over non-transformed cells (IC50s = 0.99-2 µM); reduces tumor growth in an LNCaP prostate cancer mouse xenograft model at 10 mg/kg administered five days per week for two weeks


Formal name: 3-methyl-2-[(1-hydroxy-2-naphthalenyl)methylene]hydrazide-2-thiophenecarboxylic acid

Synonyms: 

Molecular weight: 310.4

CAS: 444930-42-1

Purity: ≥98%

Formulation: A crystalline solid


Product Type|Biochemicals|Small Molecule Inhibitors|Nucleic Acid Turnover/Signaling||Research Area|Cancer|Cell Cycle|G1||Research Area|Cancer|Cell Cycle|G2/M||Research Area|Cancer|Cell Cycle|G2/S||Research Area|Epigenetics, Transcription, & Translation|RNA, DNA, & Protein Synthesis